TY - JOUR
T1 - Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial
AU - Denham, J.W.
AU - Steigler, A.
AU - Joseph, David
AU - Lamb, D.S.
AU - Spry, Nigel
AU - Duchesne, G.
AU - Atkinson, C.
AU - Matthews, J.
AU - Turner, S.
AU - Kenny, L.
AU - Tai, K.H.
AU - Gogna, N.K.
AU - Gill, S.
AU - Tan, H.
AU - Kearvell, R.
AU - Murray, J.
AU - Ebert, M.
AU - Haworth, A.
AU - Kennedy, A.
AU - Delahunt, B.
AU - Oldmeadow, C.
AU - Holliday, E.G.
AU - Attia, J.
PY - 2015
Y1 - 2015
N2 - Copyright © 2015 Elsevier Ireland Ltd. All rights reserved. BACKGROUND: The relative effects of radiation dose escalation (RDE) and androgen suppression (AS) duration on local prostatic progression (LP) remain unclear. METHODS: We addressed this in the TROG 03.04 RADAR trial by incorporating a RDE programme by stratification at randomisation. Men were allocated 6 or 18 months AS±18 months zoledronate (Z). The main endpoint was a composite of clinically diagnosed LP or PSA progression with a PSA doubling time ⩾6 months. Fine and Gray competing risk modelling with adjustment for site clustering produced cumulative incidence estimates at 6.5 years for each RDE group. RESULTS: Composite LP declined coherently in the 66, 70 and 74 Gy external beam dosing groups and was lowest in the high dose rate brachytherapy boost (HDRB) group. At 6.5 years, adjusted cumulative incidences were 22%, 15%, 13% and 7% respectively. Compared to 6 months AS, 18 months AS also significantly reduced LP (p
AB - Copyright © 2015 Elsevier Ireland Ltd. All rights reserved. BACKGROUND: The relative effects of radiation dose escalation (RDE) and androgen suppression (AS) duration on local prostatic progression (LP) remain unclear. METHODS: We addressed this in the TROG 03.04 RADAR trial by incorporating a RDE programme by stratification at randomisation. Men were allocated 6 or 18 months AS±18 months zoledronate (Z). The main endpoint was a composite of clinically diagnosed LP or PSA progression with a PSA doubling time ⩾6 months. Fine and Gray competing risk modelling with adjustment for site clustering produced cumulative incidence estimates at 6.5 years for each RDE group. RESULTS: Composite LP declined coherently in the 66, 70 and 74 Gy external beam dosing groups and was lowest in the high dose rate brachytherapy boost (HDRB) group. At 6.5 years, adjusted cumulative incidences were 22%, 15%, 13% and 7% respectively. Compared to 6 months AS, 18 months AS also significantly reduced LP (p
U2 - 10.1016/j.radonc.2015.05.016
DO - 10.1016/j.radonc.2015.05.016
M3 - Article
C2 - 26072289
SN - 0167-8140
VL - 115
SP - 301
EP - 307
JO - Radiotherapy & Oncology
JF - Radiotherapy & Oncology
IS - 3
ER -
